



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, September 23, 2022

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that its licensing partner, Boryung Corporation, has received the conditional marketing approval for Zepzelca® (lurbinectedin) by the Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar announces the approval of Zepzelca[®] (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in South Korea

- Lurbinectedin will become commercially available in South Korea in the coming months.

Madrid, September 23rd, 2022. – PharmaMar (MSE:PHM) has announced today that its licensing partner, Boryung Corporation, has received the conditional marketing approval for Zepzelca[®] (lurbinectedin) by the Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

This new approval of lurbinectedin is based on the monotherapy clinical data from the open-label, multi-center, single-arm clinical trial in 105 adult patients with relapsed SCLC (including patients with platinum-sensitive, resistant and refractory disease), that the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the US.

In November 2017, PharmaMar and Boryung signed a licensing agreement for lurbinectedin in South Korea. This approval allows Boryung to market lurbinectedin in South Korea in the following months.

The conditional approval is subject to confirmation with the LAGOON Phase III clinical trial in 2nd line SCLC, initiated in December 2021.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases



with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and currently commercializes Yondelis® (trabectedin) in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and ecubectedin. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and the United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analogue of the marine compound ET-736 isolated from the sea squirt *Ecteinacidia turbinata* in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com. Mobile: +34 669 47 18 03

Miguel Martínez-Cava – Comm. Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com